Annual Total Expenses
$206.59 M
-$41.46 M-16.71%
December 31, 2023
Summary
- As of February 7, 2025, VNDA annual total expenses is $206.59 million, with the most recent change of -$41.46 million (-16.71%) on December 31, 2023.
- During the last 3 years, VNDA annual total expenses has fallen by -$14.34 million (-6.49%).
- VNDA annual total expenses is now -16.71% below its all-time high of $248.05 million, reached on December 31, 2022.
Performance
VNDA Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Expenses
$58.65 M
-$1.97 M-3.25%
September 30, 2024
Summary
- As of February 7, 2025, VNDA quarterly total expenses is $58.65 million, with the most recent change of -$1.97 million (-3.25%) on September 30, 2024.
- Over the past year, VNDA quarterly total expenses has increased by +$1.95 million (+3.45%).
- VNDA quarterly total expenses is now -13.57% below its all-time high of $67.86 million, reached on March 31, 2022.
Performance
VNDA Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Expenses Formula
Total Expenses = Cost of Goods Sold + Operating Expenses + Non Operating Expenses
VNDA Total Expenses Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -16.7% | +3.5% |
3 y3 years | -6.5% | +3.5% |
5 y5 years | +20.6% | +3.5% |
VNDA Total Expenses Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -16.7% | at low | -13.6% | +30.9% |
5 y | 5-year | -16.7% | +1.1% | -13.6% | +30.9% |
alltime | all time | -16.7% | +2060.5% | -13.6% | +959.9% |
Vanda Pharmaceuticals Total Expenses History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $58.65 M(-3.2%) |
Jun 2024 | - | $60.62 M(+6.9%) |
Mar 2024 | - | $56.70 M(+8.3%) |
Dec 2023 | $206.59 M(-16.7%) | $52.37 M(+16.9%) |
Sep 2023 | - | $44.81 M(-8.4%) |
Jun 2023 | - | $48.92 M(-19.1%) |
Mar 2023 | - | $60.49 M(+4.6%) |
Dec 2022 | $248.05 M(+9.5%) | $57.85 M(-5.8%) |
Sep 2022 | - | $61.41 M(+0.8%) |
Jun 2022 | - | $60.93 M(-10.2%) |
Mar 2022 | - | $67.86 M(+14.3%) |
Dec 2021 | $226.52 M(+2.5%) | $59.38 M(+0.2%) |
Sep 2021 | - | $59.28 M(+6.7%) |
Jun 2021 | - | $55.53 M(+6.1%) |
Mar 2021 | - | $52.33 M(-8.5%) |
Dec 2020 | $220.93 M(+8.1%) | $57.20 M(+8.8%) |
Sep 2020 | - | $52.57 M(-0.9%) |
Jun 2020 | - | $53.04 M(-8.8%) |
Mar 2020 | - | $58.13 M(+2.5%) |
Dec 2019 | $204.38 M(+19.3%) | $56.69 M(+16.3%) |
Sep 2019 | - | $48.73 M(-0.9%) |
Jun 2019 | - | $49.16 M(-1.3%) |
Mar 2019 | - | $49.80 M(+13.5%) |
Dec 2018 | $171.38 M(-5.8%) | $43.89 M(+2.3%) |
Sep 2018 | - | $42.90 M(-1.2%) |
Jun 2018 | - | $43.44 M(+5.6%) |
Mar 2018 | - | $41.15 M(-11.4%) |
Dec 2017 | $181.99 M(+10.6%) | $46.43 M(+0.4%) |
Sep 2017 | - | $46.26 M(+5.2%) |
Jun 2017 | - | $43.98 M(-3.0%) |
Mar 2017 | - | $45.32 M(+16.5%) |
Dec 2016 | $164.59 M(+9.6%) | $38.90 M(-0.6%) |
Sep 2016 | - | $39.13 M(-4.1%) |
Jun 2016 | - | $40.82 M(-10.8%) |
Mar 2016 | - | $45.74 M(-2.2%) |
Dec 2015 | $150.11 M(+39.4%) | $46.74 M(+23.4%) |
Sep 2015 | - | $37.88 M(+14.7%) |
Jun 2015 | - | $33.04 M(+1.8%) |
Mar 2015 | - | $32.44 M(+39.3%) |
Dec 2014 | $107.71 M | $23.29 M(+43.5%) |
Date | Annual | Quarterly |
---|---|---|
Sep 2014 | - | $16.23 M(-50.0%) |
Jun 2014 | - | $32.47 M(-9.1%) |
Mar 2014 | - | $35.72 M(+115.5%) |
Dec 2013 | $55.08 M(-11.0%) | $16.57 M(+17.2%) |
Sep 2013 | - | $14.14 M(+20.5%) |
Jun 2013 | - | $11.73 M(-7.1%) |
Mar 2013 | - | $12.63 M(-17.4%) |
Dec 2012 | $61.91 M(+47.5%) | $15.30 M(+11.8%) |
Sep 2012 | - | $13.68 M(-16.9%) |
Jun 2012 | - | $16.46 M(+0.0%) |
Mar 2012 | - | $16.46 M(+15.3%) |
Dec 2011 | $41.98 M(+59.1%) | $14.28 M(+26.8%) |
Sep 2011 | - | $11.26 M(+25.9%) |
Jun 2011 | - | $8.94 M(+19.3%) |
Mar 2011 | - | $7.49 M(+15.8%) |
Dec 2010 | $26.38 M(-34.9%) | $6.47 M(-0.5%) |
Sep 2010 | - | $6.50 M(-8.8%) |
Jun 2010 | - | $7.13 M(+13.7%) |
Mar 2010 | - | $6.27 M(-54.5%) |
Dec 2009 | $40.50 M(-23.4%) | $13.79 M(+78.3%) |
Sep 2009 | - | $7.74 M(-37.7%) |
Jun 2009 | - | $12.41 M(+89.3%) |
Mar 2009 | - | $6.56 M(-14.3%) |
Dec 2008 | $52.85 M(-34.0%) | $7.65 M(-31.6%) |
Sep 2008 | - | $11.19 M(-19.7%) |
Jun 2008 | - | $13.94 M(-30.5%) |
Mar 2008 | - | $20.06 M(-9.0%) |
Dec 2007 | $80.04 M(+21.8%) | $22.05 M(-6.3%) |
Sep 2007 | - | $23.52 M(+33.3%) |
Jun 2007 | - | $17.64 M(+4.9%) |
Mar 2007 | - | $16.83 M(+35.6%) |
Dec 2006 | $65.71 M(+170.6%) | $12.41 M(-3.1%) |
Sep 2006 | - | $12.81 M(-42.0%) |
Jun 2006 | - | $22.08 M(+19.9%) |
Mar 2006 | - | $18.41 M(+160.9%) |
Dec 2005 | $24.29 M(+154.0%) | $7.06 M(+22.6%) |
Sep 2005 | - | $5.76 M(+4.0%) |
Jun 2005 | - | $5.53 M(-6.8%) |
Mar 2005 | - | $5.94 M |
Dec 2004 | $9.56 M | - |
FAQ
- What is Vanda Pharmaceuticals annual total expenses?
- What is the all time high annual total expenses for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals annual total expenses year-on-year change?
- What is Vanda Pharmaceuticals quarterly total expenses?
- What is the all time high quarterly total expenses for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals quarterly total expenses year-on-year change?
What is Vanda Pharmaceuticals annual total expenses?
The current annual total expenses of VNDA is $206.59 M
What is the all time high annual total expenses for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high annual total expenses is $248.05 M
What is Vanda Pharmaceuticals annual total expenses year-on-year change?
Over the past year, VNDA annual total expenses has changed by -$41.46 M (-16.71%)
What is Vanda Pharmaceuticals quarterly total expenses?
The current quarterly total expenses of VNDA is $58.65 M
What is the all time high quarterly total expenses for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high quarterly total expenses is $67.86 M
What is Vanda Pharmaceuticals quarterly total expenses year-on-year change?
Over the past year, VNDA quarterly total expenses has changed by +$1.95 M (+3.45%)